N-benzoylpyrazoles are novel small-molecule inhibitors of human neutrophil elastase

Journal of Medicinal Chemistry

Volumn 50, Issue 20, 2007, Pages 4928-4938

  Schepetkin, Igor A ^a   Khlebnikov, Andrei I ^b   Quinn, Mark T ^a  

^a MONTANA STATE UNIVERSITY   (United States)

^b ALTAI STATE TECHNICAL UNIVERSITY   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

BENZYL DERIVATIVE; CHYMOTRYPSIN INHIBITOR; LEUKOCYTE ELASTASE; LEUKOCYTE ELASTASE INHIBITOR; N BENZOYLPYRAZOLE DERIVATIVE; PYRAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CHEMICAL MODIFICATION; CHEMICAL REACTION KINETICS; DRUG CONFORMATION; DRUG MECHANISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SPECIFICITY; DRUG STABILITY; ENZYME ACTIVE SITE; HIGH THROUGHPUT SCREENING; LUNG DISEASE; MOLECULAR MODEL; PROTEINASE INHIBITION; STRUCTURE ACTIVITY RELATION;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CATALYTIC DOMAIN; CHYMOTRYPSIN; DATABASES, FACTUAL; DRUG STABILITY; HUMANS; HYDROLYSIS; KINETICS; LEUKOCYTE ELASTASE; MODELS, MOLECULAR; PROTEIN BINDING; PYRAZOLES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 34948887172     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm070600+     Document Type: Article

References (58)

1. Mannino, D. M. Epidemiology and global impact of chronic obstructive pulmonary disease. Semin. Respir. Crit. Care Med. 2005, 26, 204-210.
2. Rubenfeld, G. D.; Herridge, M. S. Epidemiology and outcomes of acute lung injury. Chest 2007, 131, 554-562.
3. Strausbaugh, S. D.; Davis, P. B. Cystic fibrosis: a review of epidemiology and pathobiology. Clin. Chest Med. 2007, 28, 279-288.
4. Abraham, E. Neutrophils and acute lung injury. Crit. Care Med. 2003, 31, S195-S199.
5. Moraes, T. J.; Zurawska, J. H.; Downey, G. P. Neutrophil granule contents in the pathogenesis of lung injury. Curr. Opin. Hematol. 2006, 13, 21-27.
6. Pham, C. T. Neutrophil serine proteases: specific regulators of inflammation. Nat. Rev. Immunol. 2006, 6, 541-550.
7. Faurschou, M.; Borregaard, N. Neutrophil granules and secretory vesicles in inflammation. Microbes Infect. 2003, 5, 1317-1327.
8. Stockley, R. A. Neutrophils and protease/antiprotease imbalance. Am. J. Respir. Crit. Care Med. 1999, 160, S49-S52.
9. Kawabata, K.; Hagio, T.; Matsuoka, S. The role of neutrophil elastase in acute lung injury. Eur. J. Pharmacol. 2002, 451, 1-10.
10. Moraes, T. J.; Chow, C.-W.; Downey, G. P. Proteases and lung injury. Crit. Care Med. 2003, 31, S189-S194.
11. Owen, C. A.; Campbell, E. J. The cell biology of leukocyte-mediated proteolysis. J. Leukocyte Biol. 1999, 65, 137-150.
12. Chua, F.; Laurent, G. J. Neutrophil elastase: mediator of extracellular matrix destruction and accumulation. Proc. Am. Thorac. Soc. 2006, 3, 424-427.
13. Dollery, C. M.; Owen, C. A.; Sukhova, G. K.; Krettek, A.; Shapiro, S. D.; Libby, P. Neutrophil elastase in human atherosclerotic plaques: production by macrophages. Circulation 2003, 107, 2829-2836.
14. Bedard, M.; McClure, C. D.; Schiller, N. L.; Francoeur, C.; Cantin, A.; Denis, M. Release of interleukin-8, interleukin-6, and colony-stimulating factors by upper airway epithelial cells: implications for cystic fibrosis. Am. J. Respir. Cell Mol. Biol. 1993, 9, 455-462.
15. Fitch, P. M.; Roghanian, A.; Howie, S. E.; Sallenave, J. M. Human neutrophil elastase inhibitors in innate and adaptive immunity. Biochem. Soc. Trans. 2006, 34, 279-282.
16. Carden, D.; Xiao, F.; Moak, C.; Willis, B. H.; Robinson-Jackson, S.; Alexander, S. Neutrophil elastase promotes lung microvascular injury and proteolysis of endothelial Cadherins. Am. J. Physiol. 1998, 275, H385-H392.
17. Barnes, P. J.; Stockley, R. A. COPD: current therapeutic interventions and future approaches. Eur. Respir. J. 2005, 25, 1084-1106.
18. Kardos, P.; Keenan, J. Tackling COPD: a multicomponent disease driven by inflammation. Med. Gen. Med. 2006, 8, 54.
19. Chughtai, B.; O'Riordan, T. G. Potential role of inhibitors of neutrophil elastase in treating diseases of the airway. J. Aerosol Med. 2004, 17, 289-298.
20. Tremblay, G. M.; Janelle, M. F.; Bourbonnais, Y. Anti-inflammatory activity of neutrophil elastase inhibitors. Curr. Opin. Invest. Drugs 2003, 4, 556-565.
21. Moreira, R.; Santana, A. B.; Iley, J.; Neres, J.; Douglas, K. T.; Horton, P. N.; Hursthouse, M. B. Design, synthesis, and enzymatic evaluation of N1-acyloxyalkyl- and N1-oxazolidin-2,4-dion-5-yl-substituted beta-lactams as novel inhibitors of human leukocyte elastase. J. Med. Chem. 2005, 48, 4861-4870.
22. Odagaki, Y.; Ohmoto, K.; Matsuoka, S.; Hamanaka, N.; Nakai, H.; Toda, M.; Katsuya, Y. The crystal structure of the complex of non-peptidic inhibitor of human neutrophil elastase ONO-6818 and porcine pancreatic elastase. Bioorg. Med. Chem. 2001, 9, 647-651.
23. Veale, C. A.; Bernstein, P. R.; Bohnert, C. M.; Brown, F. J.; Bryant, C.; Damewood, J. R., Jr.; Earley, R.; Feeney, S. W.; Edwards, P. D.; Gomes, B.; Hulsizer, J. M.; Kosmider, B. J.; Krell, R. D.; Moore, G.; Salcedo, T. W.; Shaw, A.; Silberstein, D. S.; Steelman, G. B.; Stein, M.; Strimpler, A.; Thomas, R. M.; Vacek, E. P.; Williams, J. C.; Wolanin, D. J.; Woolson, S. Orally active trifiuoromethyl ketone inhibitors of human leukocyte elastase. J. Med. Chem. 1997, 40, 3173-3181.
24. Doherty, J. B.; Ashe, B. M.; Argenbright, L. W.; Barker, P. L.; Bonney, R. J.; Chandler, G. O.; Dahlgren, M. E.; Dorn, C. P., Jr.; Finke, P. E.; Firestone, R. A.; Fletcher, D.; Hagmann, W. K.; Mumord, R.; O'Grady, L.; Maycock, A. L.; Pisano, J. M.; Shah, S. K.; Thompson, K. R.; Zimmerman, M. Cephalosporin antibiotics can be modified to inhibit human leukocyte elastase. Nature 1986, 322, 192-194.
25. Edwards, P. D.; Bernstein, P. R. Synthetic inhibitors of elastase. Med. Res. Rev. 1994, 14, 127-194.
26. Macdonald, S. J.; Dowle, M. D.; Harrison, L. A.; Clarke, G. D.; Inglis, G. G.; Johnson, M. R.; Shah, P.; Smith, R. A.; Amour, A.; Fleetwood, G.; Humphreys, D. C.; Molloy, C. R.; Dixon, M.; Godward, R. E.; Wonacott, A. J.; Singh, O. M.; Hodgson, S. T.; Hardy, G. W. Discovery of further pyrrolidine trans-lactams as inhibitors of human neutrophil elastase (HNE) with potential as development candidates and the crystal structure of HNE complexed with an inhibitor (GW475151). J. Med. Chem. 2002, 45, 3878-3890.
27. McBride, J. D.; Freeman, H. N.; Leatherbarrow, R. J. Selection of human elastase inhibitors from a conformationally constrained combinatorial peptide library. Eur. J. Biochem. 1999, 266, 403-412.
28. Cheng, D. H.; Shen, Q.; Qian, J.; Qian, Z.; Ye, Q. Z. Expression and purification of catalytic domain of human macrophage elastase for high throughput inhibitor screening. Acta Pharmacol. Sin. 2002, 23, 143-151.
29. Gao, F.; Du, G. H. Application of chemical arrays in screening elastase inhibitors. Comb. Chem. High Throughput Screening 2006, 9, 381-388.
30. Knight, W. B.; Green, B. G.; Chabin, R. M.; Gale, P.; Maycock, A. L.; Weston, H.; Kuo, D. W.; Westler, W. M.; Dorn, C. P.; Finke, P. E.; Hagmann, W. K.; Hale, J. J.; Liesch, J.; MacCoss, M.; Navia, M. A.; Shah, S. K.; Underwood, D.; Doherty, J. B. Specificity, stability, and potency of monocyclic δ-lactam inhibitors of human leucocyte elastase. Biochemistry 1992, 31, 8160-8170.
31. Schepetkin, I. A.; Khlebnikov, A. I.; Kirpotina, L. N.; Quinn, M. T. Novel small-molecule inhibitors of anthrax lethal factor identified by high-throughput screening. J. Med. Chem. 2006, 49, 5232-5244.
32. Schepetkin, I. A.; Kirpotina, L. N.; Khlebnikov, A. I.; Quinn, M. T. High-throughput screening for small-molecule activators of neutrophils: identification of novel N-formyl peptide receptor agonists. Mol. Pharmacol. 2007, 71, 1061-1074.
33. McGovern, S. L.; Caselli, E.; Grigorieff, N.; Shoichet, B. K. A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening. J. Med. Chem. 2002, 45, 1712-1722.
34. Blanchard, J. E.; Elowe, N. H.; Huitema, C.; Fortin, P. D.; Cechetto, J. D.; Eltis, L. D.; Brown, E. D. High-throughput screening identifies inhibitors of the SARS Coronavirus main proteinase. Chem. Biol. 2004, 11, 1445-1453.
35. Dixon, M. The determination of enzyme inhibitor constants. Biochem. J. 1953, 55, 170-171.
36. Kakiuchi, N.; Nishikawa, S.; Hattori, M.; Shimotohno, K. A high throughput assay of the hepatitis C virus nonstructural protein 3 serine proteinase. J. Virol. Methods 1999, 80, 77-84.
37. Pomarnacka, E.; Angielski, S.; Hoppe, A. Derivatives of 4-chloro-5-sulfamoylbenzoic acid. 8. Synthesis and diuretic activity of pyrazole [3,2-B] quinazoline and 1-benzoylpyrazole derivatives. Acta Pol. Pharm. 1984, 47, 141-151.
38. Wright, J. B.; Dulin, W. E.; Markillie, J. H. The antidiabetic activity of 3,5-dimethylpyrazoles. J. Med. Chem. 1964, 7, 102-105.
39. Goodell, J. R.; Puig-Basagoiti, F.; Forshey, B. M.; Shi, P. Y.; Ferguson, D. M. Identification of compounds with anti-West Nile virus activity. J. Med. Chem. 2006, 49, 2127-2137.
40. Paintz, M.; Bekemeier, H.; Metzner, J.; Wenzel, U. Pharmacological activities of a homologous series of pyrazole derivatives including quantitative structure-activity relationships (QSAR). Agents Actions, Suppl. 1982, 10, 47-58.
41. Vicentini, C. B.; Guarneri, M.; Andrisano, V.; Guccione, S.; Langer, T.; Marschhofer, R.; Chabin, R.; Edison, A. M.; Huang, X.; Knight, W. B.; Giori, P. Potential of pyrazolooxadiazinone derivatives as serine protease inhibitors. J. Enzyme Inhib. 2001, 16, 15-34.
42. Navia, M. A.; McKeever, B. M.; Springer, J. P.; Lin, T. Y.; Williams, H. R.; Fluder, E. M.; Dorn, C. P.; Hoogsteen, K. Structure of human neutrophil elastase in complex with a peptide chloromethyl ketone inhibitor at 1.84-Å resolution. Proc. Natl. Acad. Sci. U.S.A. 1989, 86, 7-11.
43. Dodson, G.; Wlodawer, A. Catalytic triads and their relatives. Trends Biochem. Sci. 1998, 23, 347-352.
44. Katona, G.; Wilmouth, R. C.; Wright, P. A.; Berglund, G. I.; Hajdu, J.; Neutze, R.; Schofield, C. J. X-ray structure of a serine protease acyl-enzyme complex at 0.95-Å resolution. J. Biol. Chem. 2002, 277, 21962-21970.
45. Vagnoni, L. M.; Gronostaj, M.; Kerrigan, J. E. 6-Acylamino-2- 1(ethylsulfonyl)oxy]-1H-isoindole-1,3-diones mechanism-based inhibitors of human leukocyte elastase and cathepsin G: effect of chirality in the 6-acylamino substituent on inhibitory potency and selectivity. Bioorg. Med. Chem. 2001, 9, 637-645.
46. Groutas, W. C.; Kuang, R.; Venkataraman, R.; Epp, J. B.; Ruan, S.; Prakash, O. Structure-based design of a general class of mechanism-based inhibitors of the serine proteinases employing a novel amino acid-derived heterocyclic scaffold. Biochemistry 1997, 36, 4739-4750.
47. Clemente, A.; Domingos, A.; Grancho, A. P.; Hey, J.; Moreira, R.; Neres, J.; Palma, N.; Santana, A. B.; Valente, E. Design, synthesis and stability of N-acyloxymethyl- and N-aminocarbonyloxymethyl-2-azetidinones as human leukocyte elastase inhibitors. Bioorg. Med. Chem. Lett. 2001, 11, 1065-1068.
48. Ohbayashi, H. Neutrophil elastase inhibitors as treatment for COPD. Expert. Opin. Invest. Drugs 2002, 11, 965-980.
49. Veale, C. A.; Bernstein, P. R.; Bryant, C.; Ceccarelli, C.; Damewood, J. R., Jr.; Earley, R.; Feeney, S. W.; Gomes, B.; Kosmider, B. J.; Steelman, G. B. Nonpeptidic inhibitors of human leukocyte elastase. 5. Design, synthesis, and X-ray crystallography of a series of orally active 5-aminopyrimidin-6-one- containing trifluoromethyl ketones. J. Med. Chem. 1995, 38, 98-108.
50. Walker, B.; Lynas, J. F. Strategies for the inhibition of serine proteases. Cell. Mol. Life Sci. 2001, 58, 596-624.
51. Vergely, I.; Laugaa, P.; Reboud-Ravaux, M. Interaction of human leukocyte elastase with a N-aryl azetidinone suicide substrate: conformational analyses based on the mechanism of action of serine proteinases. J. Mol. Graphics 1996, 14, 145, 158-167.
52. Aoyama, Y.; Uenaka, M.; Konoike, T.; Hayasaki-Kajiwara, Y.; Naya, N.; Nakajima, M. Inhibition of serine proteases: activity of 1,3-diazetidine-2,4- diones. Bioorg. Med. Chem. Lett. 2001, 11, 1691-1694.
53. Metz, W. A.; Peet, N. P. Inhibitors of human neutrophil elastase as a potential treatment for inflammatory diseases. Expert Opin. Ther. Pat. 1999, 9, 851-868.
54. Nakayama, Y.; Odagaki, Y.; Fujita, S.; Matsuoka, S.; Hamanaka, N.; Nakai, H.; Toda, M. Clarification of mechanism of human sputum elastase inhibition by a new inhibitor, ONO-5046, using electrospray ionization mass spectrometry. Bioorg. Med. Chem. Lett. 2002, 12, 2349-2353.
55. Burgi, H. B.; Dunitz, J. D.; Lehn, J. M.; Wipff, G. Stereochemistry of reaction paths at carbonyl centers. Tetrahedron 1974, 30, 1563-1572.
56. Forist, A. A.; Weber, D. J. Kinetics of hydrolysis of hypoglycemic 1-acyl 3,5-dimethylpyrazoles. J. Pharm. Sci. 1973, 62, 318-319.
57. Morris, G. M.; Goodsell, D. S.; Halliday, R. S.; Huey, R.; Hart, W. E.; Belew, R. K.; Olson, A. J. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J. Comput. Chem. 1998, 19, 1639-1662.
58. Peters, M. B.; Merz, K. M. Semiempirical comparative binding energy analysis (SE-COMBINE) of a series of trypsin inhibitors. J. Chem. Theory Comput. 2006, 2, 383-399.